Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia

Leukemia and Lymphoma

Volumn 54, Issue 3, 2013, Pages 483-490

  Kasamon, Yvette L ^a   Brodsky, Robert A ^a   Borowitz, Michael J ^a   Ambinder, Richard F ^a   Crilley, Pamela A ^b   Cho, Steve Y ^a   Tsai, Hua Ling ^a   Smith, B Douglas ^a   Gladstone, Douglas E ^a   Carraway, Hetty E ^a   Huff, Carol Ann ^a   Matsui, William H ^a   Bolaños Meade, Javier ^a   Jones, Richard J ^a   Swinnen, Lode J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

Atypical Burkitt lymphoma; Burkitt lymphoma; Cyclophosphamide; Unclassifiable B cell lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; FOLINIC ACID; MESNA; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SPINAL; KAPLAN-MEIER ESTIMATE; LEUKEMIA; MALE; METHOTREXATE; MIDDLE AGED; MUCOSITIS; NEUTROPENIA; PREDNISONE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84873372346     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.715346     Document Type: Article

References (31)

1. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002;13: 1264-1274.
2. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996;14: 925-934.
3. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106: 1569-1580.
4. Kelly JL, Toothaker SR, Ciminello L, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma 2009;9: 307-310.
5. Divine M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 2005;16: 1928-1935.
6. Lee EJ, Petroni GR, Schiffer CA, et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of Cancer and Leukemia Group B study 9251. J Clin Oncol 2001;19: 4014-4022.
7. Burkitt D. Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer 1967;20: 756-759.
8. Traore F, Coze C, Atteby JJ, et al. Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 2011;56: 70-76.
9. Gladstone DE, Bolaños-Meade J, Huf CA, et al. High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma 2011;52: 2076-2081.
10. Brodsky RA. High-dose cyclophosphamide for autoimmunity and alloimmunity. Immunol Res 2010;47: 179-184.
11. DeZern AE, Petri M, Drachman DB, et al. High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. Medicine (Baltimore) 2011;90: 89-98.
12. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365: 1647-1656.
13. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009;6: 638-647.
14. Anderson JR, Wilson JF, Jenkin DT, et al. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983;308: 559-565.
15. Mazza JJ, Hines JD, Andersen JW, et al. Aggressive chemotherapy in the treatment of Burkitt's and non-Burkitt's unDifferentiated lymphoma. Leuk Lymphoma 1995;18: 289-296.
16. Swerdlow SH, Campo E, Harris NL, et al. WHO classif cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC: 2008.
17. National Cancer Institute Common Terminology Criteria, version 3. 0. 2006. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
18. Cheson BD, Pffstner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25: 579-586.
19. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17: 2461-2470.
20. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94: 496-509.
21. Cheson BD, Horning SJ, Coifer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17: 1244-1253.
22. Li S, Lin P, Fayad LE, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012;25: 145-156.
23. Nitta E, Izutsu K, Sato T, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007;18: 364-369.
24. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer 2004;100: 1438-1448.
25. LaCasce A, Howard O, Li S, et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved ef cacy with decreased toxicity. Leuk Lymphoma 2004;45: 761-767.
26. Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and "unclassifable"highly aggressive B-cell lymphoma. Br J Haematol 2012;156: 234-244.
27. Barta SK, Lee JY, Kaplan LD, et al. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2011 Dec 16. [Epub ahead of print]
28. Noy A, Kaplan L, Lee J. Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): preliminary results of a prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC). Blood 2009;114(Suppl. 1): Abstract 3673.
29. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010;28: 3115-3121.
30. Rizzieri DA, Johnson JL, Byrd JC, et al. Effcacy and toxicity of rituximab and brief duration, high intensity chemotherapy with f lgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) Study 10002. Blood 2010;116(Suppl. 1): Abstract 858.
31. Barnes BA, LaCasce AS, Feng Y, et al. Rituximab added to CODOX-M/IVAC has no clear benef t compared to CODOX-M/IVAC alone in adult patients with Burkitt lymphoma. Blood 2009: 114(Suppl. 1): Abstract 1667.